HC Wainwright & Co. Upgrades Cidara Therapeutics to Buy, Announces $24 Price Target
Cidara Therapeutics Analyst Ratings
Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Needham Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $25
Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Buy Rating Justified by Cidara Therapeutics' Upcoming Clinical Trials and Expanding Oncology Pipeline
Needham: Maintaining the Cidara Therapeutics (CDTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.00 to $25.00.
Cidara Therapeutics Analyst Ratings
Cantor Fitzgerald: Reiterates Cidara Therapeutics' (CDTX.US) Accumulation Rating.
Cidara Therapeutics Analyst Ratings
HC Wainwright & Co. : The Cidara Therapeutics (CDTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $6.00 to $6.00.
Cidara Therapeutics Analyst Ratings
Buy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program Developments
Analysts' Top Healthcare Picks: Cidara Therapeutics (CDTX), Enveric Biosciences (ENVB)
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Cidara Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Cidara Therapeutics Analyst Ratings